Novo Nordisk ASWBO:NNO2 -1.23%71 EV-to-EBIT is 9.69 as of Jul. 08, 2026, which is 48% below its 10-year median of 18.50. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.11 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Novo Nordisk AS ranks better than 72.46% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Novo Nordisk AS's Enterprise Value for the quarter that ended in Mar. 2026 was €154,635 Mil.
Novo Nordisk AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €21,404 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS EV-to-EBIT Related Terms
Novo Nordisk AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's EV-to-EBIT falls into.
Novo Nordisk AS's current Enterprise Value is €207,475 Mil.
Novo Nordisk AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €21,404 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (WBO:NNO2) has a EV-to-EBIT of 9.69 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Novo Nordisk AS and its competitors. This is 48% below median its historical median of 18.50. Over the past decade, Novo Nordisk AS's EV-to-EBIT has ranged from 7.37 to 39.49. According to the industry distribution chart, Novo Nordisk AS ranks #190 out of 690 companies in the Drug Manufacturers industry, placing it in the top 27.5%.
Is Novo Nordisk AS's EV-to-EBIT too high?
Novo Nordisk AS's current EV-to-EBIT of 9.69 is 48% below median its 10-year median of 18.50. Over the past 10 years, this metric has ranged from a low of 7.37 to a high of 39.49. The Drug Manufacturers industry median EV-to-EBIT is 15.91. Novo Nordisk AS's value of 9.69 is 39.1% below this industry median. Based on the distribution chart, Novo Nordisk AS ranks #190 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #190 out of 690 companies for EV-to-EBIT. This puts Novo Nordisk AS in the upper half of its industry. The industry median EV-to-EBIT is 15.91. Novo Nordisk AS's value of 9.69 is 39.1% below this benchmark. Historically, Novo Nordisk AS's own EV-to-EBIT has ranged from 7.37 to 39.49 over the past decade. While the company's 10-year median is 18.50 vs. the industry median of 15.91, Novo Nordisk AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.91, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current EV-to-EBIT of 9.69 is 39.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current EV-to-EBIT is 9.69, which is 48% below median its own 10-year median of 18.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.11, compared to a current price of €43.06 — trading 64.2% below its estimated fair value. The current EV-to-EBIT is 9.69, which is 48% below median its 10-year median of 18.50 and 39.1% below the Drug Manufacturers industry median of 15.91. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current EV-to-EBIT is 9.69 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.06 is trading 64.2% below its estimated GF Value™ of €120.11.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
EV-to-EBIT: 9.69 (48% below median its 10-year median of 18.50)
GF Value™: €120.11 vs. price of €43.06 (64.2% below fair value)
Industry Position: 39.1% below the Drug Manufacturers median (#190 of 690)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score
Get the complete analysis for WBO:NNO2
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
